Black Diamond Therapeutics
IPO
Defeating Cancer Resistance
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- blackdiamondtherapeutics.com
- Total Funding
- $170.0M
- Last Round
- $85.0M Series CDec 2019
About
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target broad families of oncogenic mutations in clinically validated targets. The company's lead programs focus on non-small cell lung cancer (NSCLC) and glioblastoma (GBM), with silevertinib as its clinical-stage brain-penetrant EGFR inhibitor. Black Diamond trades on Nasdaq under the ticker BDTX.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account